Intraperitoneal Chemotherapy
Neoadjuvant immunotherapy in a solitary, isolated peritoneal mesothelioma involving the abdominal wall: a case report
Immunotherapy 2025 July [Link] Parsa Charkhchi, Ryan Le, Taryn E Cazzolli, Raina R Flores, Roberto A Martinez, Supreet Kaur, Mio Kitano Abstract Mesothelioma is a rare neoplasm with a minority of cases originating from the peritoneum. Patients are generally treated with a combination of cytoreductive surgery, hyperthermic intraperitoneal chemotherapy, and various systemic therapies. In recent…
Read MoreNational Guidelines for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Peritoneal Malignancies: A Worldwide Systematic Review and Recommendations of Strength Analysis
Annals of Surgical Oncology 2025 August [Link] Marco Tonello, Carola Cenzi, Elisa Pizzolato, Manuela Martini, Pierluigi Pilati, Antonio Sommariva Abstract Background: National guidelines (GLs) for surgical cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in the management of peritoneal malignancies (PMs) vary across countries, scientific societies, and government agencies. This study aimed to systematically review and…
Read MoreEnhanced Detection of Recurrent Diffuse Malignant Peritoneal Mesothelioma Using 68 Ga-FAPI PET/CT Compared to 18 F-FDG PET/CT: A Case Report
World Journal of Nuclear Medicine 2025 March 12 [Link] Marwah Abdulrahman, Ula Al-Rasheed, Ali Dabous, Akram Al-Ibraheem Abstract Diffuse malignant peritoneal mesothelioma (DMPM) is a rare and aggressive subtype of epithelioid mesothelioma that arises from the lining of the abdominal cavity. While the applications of traditional fluorine-18 fluorodeoxyglucose ( 18 F-FDG) positron emission tomography/computed tomography…
Read MorePrognostic Factors of Long-Term Survival and Conditional Survival Analysis in MPM Patients Treated with CRS+HIPEC: A Retrospective Study of Two Centers
Annals of Surgical Oncology 2024 November 13 [Link] Xin-Li Liang, Yan-Dong Su, Xin-Bao Li, Yu-Bin Fu, Ru Ma, Rui Yang, He-Liang Wu, Yu-Run Cui, Yan Li Abstract Objectives: This study was designed to explore the survival benefit factors of malignant peritoneal mesothelioma (MPM) patients after cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) and to…
Read MorePerfusion Strategies for Cytoreductive Surgery With Heated Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma
Journal of Surgical Oncology 2024 September 10 [Link] Claire Drigotas, Alexander W Loftus, John B Ammori, Luke D Rothermel, Richard S Hoehn Abstract Cytoreductive surgery (CRS) with heated intraoperative intraperitoneal chemotherapy (HIPEC) has been shown to improve survival for patients with malignant peritoneal mesothelioma (MPM). Presently, there is no standardized HIPEC protocol with respect to…
Read MoreDrug sensitivity tumor cell clusters in malignant peritoneal mesothelioma
Journal of Surgical Oncology 2024 August 24 [Link] Yan-Dong Su, Ru Ma, Yu-Bin Fu, He-Liang Wu, Xin-Li Liang, Yi-Tong Liu, Yang Yu, Zhi-Ran Yang, Yan Li Abstract Background: To explore the most effective adjuvant chemotherapy regimen for malignant peritoneal mesothelioma (MPM) through patient derived tumor-like cell clusters (PTC) drug sensitivity test. Methods: PTC were cultured…
Read MoreStemness and hybrid epithelial-mesenchymal profiles guide peritoneal dissemination of malignant mesothelioma and pseudomyxoma peritonei
International Journal of Cancer 2024 August 15 [Link] Nayana Lazzari, Giulia Rigotto, Barbara Montini, Paola Del Bianco, Elena Moretto, Federica Palladino, Rocco Cappellesso, Marco Tonello, Carola Cenzi, Antonio Scapinello Maria Assunta Piano, Carlo Riccardo Rossi, Piero Dalerba, Pierluigi Pilati, Antonio Sommariva, Maria Luisa Calabrò Abstract Intrabdominal dissemination of malignant mesothelioma (MM) and pseudomyxoma peritonei (PMP)…
Read MoreCurrent clinical practices of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
Innovative Surgical Sciences 2024 March 14 [Link] Miklos Acs, Maximilian Babucke, Maximilian Jusufi, Zsolt Kaposztas, Przemyslaw Slowik, Matthias Hornung, Hans J Schlitt, Ivan Panczel, Judit Hevesi, Jonas Herzberg, Tim Strate, Pompiliu Piso Abstract Treatment of peritoneal surface malignancies makes physicians face demanding and new-fangled problems, as there are many uncertain aspects considering the outcomes of…
Read MoreA systematic review of minimally invasive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal malignancy
ANZ Journal of Surgery 2024 May 15 [Link] Lauren Cohen, Faizah Alam, Michael P Flood, Helen Mohan, Anshini Jain, Glen Guerra, Alexander G Heriot, Joseph C H Kong Abstract Background: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is traditionally a maximally invasive operation with a large abdominal incision and multi-visceral resections. However, to minimize…
Read MoreThe role of cytoreductive surgery and HIPEC for the treatment of primary and secondary peritoneal malignancies-experience from a tertiary care center in Germany
Langenbeck’s Archives of Surgery 2024 April 8 [Link] Mikko Reese, Ann-Kathrin Eichelmann, Tobias M Nowacki , Andreas Pascher, Judith C Sporn Abstract Purpose: Peritoneal surface malignancies (PSM) are commonly known to have a dismal prognosis. Over the past decades, novel techniques such as cytoreductive surgery (CRS), hyperthermic intraperitoneal chemotherapy (HIPEC), and pressurized intraperitoneal aerosol chemotherapy…
Read More